pharmaphorum8mon
Lilly’s Retevmo cleared for RET-positive child cancers
advanced or metastatic thyroid cancer with a RET gene fusion that can’t be treated with radioactive iodine therapy, and locally advanced or metastatic solid tumours with a RET gene fusion that ...
Armed robbery in Revesby3d
Cheaper Medicine For Lung Cancer Patients
The Australian Government is listing Retevmo® (selpercatinib) on the Pharmaceutical Benefits Scheme (PBS) for the first time ...
ascopubs.org9d
Rate of gene fusion/rearrangement identification in GI cancers as sequencing evolved from limited panels to whole exome sequencing.
Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers. Gene rearrangements/fusions identified per year.
pharmaphorum3d
FDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancers
The US regulator says Retevmo (selpercatinib, formerly LOXO-292) can be used to treat lung and thyroid cancers with a mutation or fusion in the RET gene, specifically non-small cell lung cancer ...
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
WebMD6mon
Retevmo: Targeted Therapy for Lung Cancer Treatment
Retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET).
科学技術振興機構2y
Research Results
developed a new screening method. At CREST in 2007, Professor Mano discovered the EML4-ALK fusion gene; at Research Acceleration in 2012, he discovered the RET and ROSI fusion genes, which are all ...